Breaking News Instant updates and real-time market news.

MGEN

Miragen Therapeutics

$4.18

0.03 (0.72%)

07:10
01/10/19
01/10
07:10
01/10/19
07:10

Miragen Therapeutics announces data from Phase 1 cobomarsen trial

Miragen Therapeutics announced data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma, or CTCL, and in adult T-cell leukemia/lymphoma, or ATLL. The company will also discuss initial clinical experience in treating diffuse large B-cell lymphoma, or DLBCL, patients with cobomarsen. The data will be presented at the 11th Annual T-Cell Lymphoma Forum. Updated durability data for the 300mg IV infusion cohort of the Phase 1 cobomarsen clinical trial, which is the dose and route of administration being used in the ongoing SOLAR Phase 2 clinical trial, showed that four of eight patients achieved an objective response with greater than four months of durability. The Phase 2 SOLAR trial will evaluate the safety and efficacy of cobomarsen given by intravenous infusion in an active control comparison trial versus Zolinza in patients with CTCL. ORR4 is the primary endpoint that will be used in the SOLAR trial. Based on discussions with the FDA, Miragen believes the results from the SOLAR trial could allow the company to apply for accelerated approval in the United States. Data from the ongoing Phase 1 clinical trial in ATLL has shown that cobomarsen had a favorable safety and tolerability profile with no serious adverse events attributed to the drug candidate in the clinical trial and no documented opportunistic infections, which are common in patients with the disease. Four patients who demonstrated a partial response after chemotherapy have maintained their responses while on cobomarsen monotherapy. Two of these patients have been stable for more than a year. There is evidence of disease stabilization in five patients on cobomarsen, as shown in both peripheral blood and lymph nodes, without negatively impacting the number of normal immune cells. One of these lymphomatous patients with significant adenopathy prior to enrollment has remained stable on cobomarsen, as measured by CT scans, for six months. This includes an objective improvement in three out of four measurable abnormal nodes since initiating cobomarsen therapy.

  • 10

    Jan

MGEN Miragen Therapeutics
$4.18

0.03 (0.72%)

03/29/18
JEFF
03/29/18
INITIATION
Target $14
JEFF
Buy
Miragen Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Eun Yang started Miragen Therapeutics with a Buy rating and $14 price target. The analyst believes the company has a leading position in microRNA therapy and thinks early clinical data could expand the "relatively inexpensive" valuation.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $19
OPCO
Outperform
Miragen Therapeutics price target raised to $19 from $13 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target fro Miragen Therapeutics to $19 from $13 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
12/31/18
RILY
12/31/18
INITIATION
Target $18.5
RILY
Buy
Miragen Therapeutics resumed with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico resumed coverage of Miragen Therapeutics and kept his firm's Buy rating and $18.50 price target on the shares.
01/04/19
BARD
01/04/19
INITIATION
Target $10
BARD
Outperform
Miragen Therapeutics initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Miragen Therapeutics with an Outperform rating, citing its near cash valuation, potential for its drug candidate in mycosis fungoides, and its undervalued MicroRNA platform. Kumar has a $10 price target on Miragen Therapeutics shares.

TODAY'S FREE FLY STORIES

03:00
01/17/19
01/17
03:00
01/17/19
03:00
General news
FX Update: An abatement in risk appetite has impacted currencies »

FX Update: An abatement…

01:50
01/17/19
01/17
01:50
01/17/19
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

RVNC

Revance

$18.11

-2.11 (-10.44%)

21:05
01/16/19
01/16
21:05
01/16/19
21:05
Syndicate
Revance 5.9M share Secondary priced at $17.00 »

Goldman Sachs, Cowen and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MRTX

Mirati Therapeutics

$62.51

-2.33 (-3.59%)

20:49
01/16/19
01/16
20:49
01/16/19
20:49
Syndicate
Mirati Therapeutics 1.6M share Spot Secondary priced at $62.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

BREW

Craft Brew

$15.50

0.19 (1.24%)

20:45
01/16/19
01/16
20:45
01/16/19
20:45
Initiation
Craft Brew initiated at Maxim »

Craft Brew initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROX

Castle Brands

$0.91

0.0122 (1.36%)

20:41
01/16/19
01/16
20:41
01/16/19
20:41
Initiation
Castle Brands initiated at Maxim »

Castle Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRT

PermRock Royalty Trust

$9.61

-0.39 (-3.90%)

20:39
01/16/19
01/16
20:39
01/16/19
20:39
Downgrade
PermRock Royalty Trust rating change at Stifel »

PermRock Royalty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBCI

Glacier Bancorp

$42.87

1.36 (3.28%)

20:38
01/16/19
01/16
20:38
01/16/19
20:38
Hot Stocks
Glacier Bancorp acquires FNB Bancorp »

Glacier Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 12

    Mar

ERJ

Embraer

$22.81

-0.59 (-2.52%)

20:34
01/16/19
01/16
20:34
01/16/19
20:34
Downgrade
Embraer rating change at Morgan Stanley »

Embraer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AICAF

Air China

$0.00

(0.00%)

20:32
01/16/19
01/16
20:32
01/16/19
20:32
Upgrade
Air China rating change at HSBC »

Air China upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEA

China Eastern Airlines

$28.64

-0.09 (-0.31%)

20:26
01/16/19
01/16
20:26
01/16/19
20:26
Upgrade
China Eastern Airlines rating change at HSBC »

China Eastern Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$44.48

1.59 (3.71%)

, BBT

BB&T

$47.55

1.2 (2.59%)

20:25
01/16/19
01/16
20:25
01/16/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MS

Morgan Stanley

$44.48

1.59 (3.71%)

BBT

BB&T

$47.55

1.2 (2.59%)

PPG

PPG

$102.58

1.58 (1.56%)

MTB

M&T Bank

$154.45

3.04 (2.01%)

KEY

KeyCorp

$16.75

0.44 (2.70%)

FAST

Fastenal

$54.11

-0.47 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 11

    Feb

  • 23

    May

  • 18

    Oct

FDC

First Data

$21.27

3.72 (21.20%)

20:07
01/16/19
01/16
20:07
01/16/19
20:07
Downgrade
First Data rating change at Goldman Sachs »

First Data downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

VEON

Veon

$2.56

-0.03 (-1.16%)

19:44
01/16/19
01/16
19:44
01/16/19
19:44
Downgrade
Veon rating change at VTB Capital »

Veon downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,682.84

7.84 (0.47%)

19:22
01/16/19
01/16
19:22
01/16/19
19:22
Hot Stocks
Amazon announces AWS Backup service »

Amazon Web Service, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 28

    Jan

  • 20

    Feb

  • 03

    Mar

GS

Goldman Sachs

$197.03

17.12 (9.52%)

19:09
01/16/19
01/16
19:09
01/16/19
19:09
Periodicals
WSJ's "Heard on the Street" column says to look past Goldman Sachs Q4 glitter »

The Wall Street…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

TSLA

Tesla

$346.03

1.78 (0.52%)

18:57
01/16/19
01/16
18:57
01/16/19
18:57
Periodicals
CA makes up large portion of Tesla Model 3 registrations in 2018, Bloomberg says »

The state of California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

CARS

Cars.com

$23.14

-0.26 (-1.11%)

, MNKD

MannKind

$1.32

-0.06 (-4.35%)

18:46
01/16/19
01/16
18:46
01/16/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Cars.com (CARS)…

CARS

Cars.com

$23.14

-0.26 (-1.11%)

MNKD

MannKind

$1.32

-0.06 (-4.35%)

FOLD

Amicus

$12.18

0.19 (1.58%)

FUL

H.B. Fuller

$43.35

0.09 (0.21%)

PLXS

Plexus

$54.88

1.195 (2.23%)

CSX

CSX

$65.36

0.27 (0.41%)

KMI

Kinder Morgan

$17.46

0.15 (0.87%)

AA

Alcoa

$29.02

0.13 (0.45%)

ACB

Aurora Cannabis

$7.33

0.35 (5.01%)

MRTX

Mirati Therapeutics

$62.51

-2.33 (-3.59%)

AAPL

Apple

$154.88

1.84 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

  • 29

    Jan

  • 29

    Jan

  • 10

    Feb

  • 11

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    May

  • 17

    Jan

BAC

Bank of America

$28.44

1.89 (7.12%)

18:46
01/16/19
01/16
18:46
01/16/19
18:46
Periodicals
BofA's global investment banking head to leave bank, FT reports »

Bank of America's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 12

    Feb

  • 03

    Mar

NEWR

New Relic

$90.47

1.38 (1.55%)

18:44
01/16/19
01/16
18:44
01/16/19
18:44
Hot Stocks
New Relic CEO: 'We are an app-centric company' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 06

    Feb

  • 25

    Feb

  • 14

    Mar

TME

Tencent Music

$12.99

0.57 (4.59%)

18:33
01/16/19
01/16
18:33
01/16/19
18:33
Initiation
Tencent Music initiated at JPMorgan »

Tencent Music initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASCMA

Ascent Capital

$0.40

-0.0499 (-11.09%)

18:27
01/16/19
01/16
18:27
01/16/19
18:27
Hot Stocks
Ascent Capital announces strategic review »

Ascent Capital Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMS

CMS Energy

$50.56

0.34 (0.68%)

18:19
01/16/19
01/16
18:19
01/16/19
18:19
Initiation
CMS Energy initiated at Goldman Sachs »

CMS Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

DTE

DTE Energy

$111.73

0.48 (0.43%)

18:15
01/16/19
01/16
18:15
01/16/19
18:15
Initiation
DTE Energy initiated at Goldman Sachs »

DTE Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:15
01/16/19
01/16
18:15
01/16/19
18:15
General news
Breaking General news story  »

Minneapolis Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.